Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 ...

Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Q2 2025 Management View Kristin C. Peck, CEO, reported "strong broad-based 8% organic operational revenue growth" and noted ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET. Company Participants. Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor ...

NYSE:ZTS 1 Year Share Price vs Fair Value Explore Zoetis's Fair Values from the Community and select yours Zoetis ...

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing ...